Azenta AZTA Multiomics — Operating Income (Loss)

Similar metrics at other companies

DHRLife Sciences — Operating Income (Loss)

$225M+11.9%

AATMixed-use — Operating Income (Loss)

$5.22M-1.8%

AATMultifamily — Operating Income (Loss)

$10.03M+4.7%

AGNTAll Other Segments — Operating Income

-$194K+88.2%

JAN

JANBiotech — Operating Income

-$177K+67.2%

TMOLife Sciences Solutions — Operating Income (Loss)

$954M+14.4%

Questions, answered.

What is Azenta's multiomics — operating income (loss)?

Azenta (AZTA) reported multiomics — operating income (loss) of -$10.07M in Q1 2026.

How has Azenta's multiomics — operating income (loss) changed year-over-year?

Azenta's multiomics — operating income (loss) decreased by 81.8% year-over-year, from -$5.54M to -$10.07M.

What does multiomics — operating income (loss) mean?

The profit or loss generated by the Multiomics segment after deducting both the cost of revenue and operating expenses from total segment revenue. This represents the core operational performance of the business unit before interest, taxes, and corporate-level allocations. It is a key indicator of the segment's ability to generate sustainable returns from its core activities.